Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-03-2016 | Review Article

Multiple Myeloma: Treatment is Getting Individualized

Author: M. B. Agarwal

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2016

Login to get access

Abstract

Multiple myeloma (MM) is a heterogeneous disease with varied outcome. The novel agents including two major classes of drugs; the immunomodulatory drugs and the proteasome inhibitors with unprecedented response rates, have replaced conventional chemotherapy. With monoclonal antibodies on the horizon, outcome of this disorder will further improve. Progression in risk stratification systems has made it possible to predict the disease course as well as outcome in myeloma patients with disease categorization into low to high risk. In addition, detection of minimal residual disease by serum free light chain assay, flow cytometry, molecular techniques like polymerase chain reaction and positron emission tomography scan is playing an important role in modifying the treatment. An extensive research in the disease biology has improved our knowledge regarding interplay between myeloma cells and elements of the bone marrow microenvironment which contribute to sustain proliferation and survival as well as de novo drug resistance. Again, insight into the role of genetic and epigenetic interactions in MM has exposed new molecular targets. All these have opened the gateway for novel therapeutic strategies with focus on risk based individualized therapy.
Literature
1.
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520PubMedCentralCrossRefPubMed
2.
Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al (2009) Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 84(12):1095–1110PubMedCentralCrossRefPubMed
3.
Ghalaut PS, Chaudhuri S, Singh R (2013) Recent advances in diagnosis and management of multiple myeloma: an update. In: The Association of Physicians of India, Medicine Update 2013, Section 10 Hematology, Chapter 80, pp 360–365
4.
5.
Programme National Cancer Registry (2005) Two year report of the population based cancer registries 1999–2000. Indian Council of Medical Research, New Delhi
6.
Kumar L, Verma R, Radhakrishnan VR (2010) Recent advances in the management of multiple myeloma. Natl Med J India 23(4):210–218PubMed
7.
Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89CrossRefPubMed
8.
Forgeson GV, Selby P, Lakhani S, Zulian G, Viner C, Maitland J et al (1988) Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 58:469–473PubMedCentralCrossRefPubMed
9.
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842–854CrossRefPubMed
10.
Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Bladé J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420CrossRefPubMed
11.
Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18):4696–4700PubMedCentralCrossRefPubMed
12.
Niels WCJ, Donk VD, Sonneveld P (2014) Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin N Am 28:791–813CrossRef
13.
Girnius S, Munshi NC (2013) Individualized therapy in multiple myeloma: are we there? Semin Oncol 40(5):567–576CrossRefPubMed
14.
Flactif M, Zandecki M, Laï JL, Bernardi F, Obein V, Bauters F et al (1995) Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9:2109–2114PubMed
15.
Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S et al (2014) IMWG consensus on risk stratification in multiple myeloma. Leukemia 28:269–277CrossRefPubMed
16.
Ross FM, vet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O’Connor S et al (2012) Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272–1277PubMedCentralCrossRefPubMed
17.
Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL et al (2009) Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27:4585–4590PubMedCentralCrossRefPubMed
18.
Broyl A, Hose D, Lokhorst H, Knegt Y, Peeters J, Jauch A et al (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 16(14):2543–2553CrossRef
19.
Chi J, Ballabio E, Chen X, Kušec R, Taylor S, Hay D et al (2011) MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 6:23PubMedCentralCrossRefPubMed
20.
Anderson KC (2012) The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30:445–452CrossRefPubMed
21.
22.
Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A et al (2011) Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. Clin Lymphoma Myeloma Leuk 11(1):44–49CrossRefPubMed
23.
Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27:5008–5014CrossRefPubMed
24.
25.
Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A et al (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953–1959CrossRefPubMed
26.
27.
Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 28(12):2077–2084CrossRefPubMed
28.
Munshi NC, Anderson KC (2013) Minimal residual disease in multiple myeloma. J Clin Oncol 31(20):2523–2526CrossRefPubMed
29.
Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R et al (2014) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20):3073–3079PubMedCentralCrossRefPubMed
30.
Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr et al (2007) Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 25:1121–1128CrossRefPubMed
31.
Bartel TB, Haessler J, Brown TLY, Shaughnessy JD Jr, van Rhee F, Anaissie E et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 114:2068–2076PubMedCentralCrossRefPubMed
32.
Puente PDL, Muz B, Azab F, Luderer M, Azab AK (2014) Molecularly targeted therapies in multiple myeloma. Hindawi Publishing Corporation Leukemia Research and Treatment, Article ID 976567. doi:10.​1155/​2014/​976567
33.
34.
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101:540–545PubMedCentralCrossRefPubMed
35.
Jagannath S, Dimopoulos MA, Lonial S (2010) Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 34:1111–1118CrossRefPubMed
36.
37.
Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C et al (2007) Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138:783–791CrossRefPubMed
38.
39.
Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C et al (2011) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma 52:2308–2315CrossRefPubMed
40.
Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M et al (2010) Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 150:428–437PubMedCentralPubMed
41.
Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S et al (2007) Neutralizing B cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903–5909CrossRefPubMed
42.
Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675–6682CrossRefPubMed
43.
Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA et al (2011) RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 117:3847–3857PubMedCentralCrossRefPubMed
44.
Hideshima T, Anderson KC (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2:927–937CrossRefPubMed
45.
Kroger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H et al (2013) Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogenic tandem transplantation in multiple myeloma. Biol Blood Marrow Transpl 19:398–404CrossRef
46.
Sugumar D, Keller J, Vij R (2015) Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med 8:23–33PubMedCentralPubMed
47.
48.
Richardson PG, Laubach JP, Munshi NC, Anderson KC (2014) Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematol Am Soc Hematol Educ Progr 1:255–261CrossRef
49.
Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91–101PubMedCentralCrossRefPubMed
50.
Xie Z, Chng WJ (2014) MMSET: role and therapeutic opportunities in multiple myeloma. BioMed Res Int, Article ID 636514
51.
Misso G, Zappavigna S, Castellano M, Rosa GD, Martino MT, Tagliaferri P (2013) Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther 13(1):S95–S109CrossRefPubMed
52.
Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M et al (2010) Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24(10):1769–1778CrossRefPubMed
53.
54.
Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98(7):2229–2238CrossRefPubMed
55.
56.
Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P et al (2015) Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. doi:10.​1111/​ejh.​12491
57.
58.
59.
Biran N, Jagannath S, Chari A (2013) Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clin Adv Hematol Oncol 11(8):489–503PubMed
60.
Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandemstem-cell transplantation. Blood 108:1724–1732PubMedCentralCrossRefPubMed
61.
Shaughnessy J (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10(Suppl 1):117–126CrossRefPubMed
62.
Yu W, Li J, Chen L (2014) Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. Int J Clin Exp Med 7(11):4051–4062PubMedCentralPubMed
63.
Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519–4529CrossRefPubMed
64.
Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C et al (2008) Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49(5):890–895CrossRefPubMed
Metadata
Title
Multiple Myeloma: Treatment is Getting Individualized
Author
M. B. Agarwal
Publication date
01-03-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0575-5

Other articles of this Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue

Original Article

The Effect of Hydroxyurea Therapy in Bahraini Sickle Cell Disease Patients

Original Article

Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2)

Editorial

Changing Times for the IJHBT

Original Article

Obstetric Complications and Management in Chronic Myeloid Leukemia

Original Article

Serological Assessment for Leishmania donovani Infection in Blood Donors of Sunsari District, Dharan, Nepal

BriefCommunication

Enhancement of Antibody Titre and Development of Additional Red Cell Alloantibodies Following Intrauterine Transfusion
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits